Journal
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
Volume 16, Issue 5, Pages 479-490Publisher
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2018.0026
Keywords
-
Categories
Funding
- AstraZeneca
- Celldex Therapeutics
- Celgene Corporation
- Genentech
- Jazz Pharmaceuticals, Inc.
- Novartis Pharmaceuticals Corporation
- Seattle Genetics, Inc
- AbbVie
- Merck Co., Inc.
- NOVOCURE
Ask authors/readers for more resources
The NCCN Guidelines for Head and Neck (H&N) Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the H&N, and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding evaluation and treatment of nasopharyngeal carcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available